Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Voclosporin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP3CA known ✓ | Q08209 | 4/20 | 0.86 |
| ▸ | ABCB1 | P08183 | 13/20 | 0.86 |
| ▸ | PPIA | P62937 | 5/20 | 0.86 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | NPC1 | O15118 | 1/20 | 0.86 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.86 |
| ▸ | GMNN | O75496 | 1/20 | 0.86 |
| ▸ | USP2 | O75604 | 1/20 | 0.86 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.86 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.86 |
| ▸ | POLB | P06746 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | MAPT | P10636 | 1/20 | 0.86 |
| ▸ | RARB | P10826 | 1/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.86 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.86 |
| ▸ | TACR2 | P21452 | 1/20 | 0.86 |
| ▸ | PPIB | P23284 | 1/20 | 0.86 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Voclosporin SCHEMBL31152864 | 1.00 | ABCB1 (0.86) | ABCB1PPIAPPP3CAMEN1NPC1 | |
| Voclosporin SCHEMBL29190935 | 1.00 | ABCB1 (0.86) | ABCB1PPIAPPP3CAMEN1NPC1 | |
| Voclosporin SCHEMBL25643987 | 1.00 | ABCB1 (0.86) | ABCB1PPIAPPP3CAMEN1NPC1 | |
| Voclosporin SCHEMBL25643982 | 1.00 | ABCB1 (0.86) | ABCB1PPIAPPP3CAMEN1NPC1 | |
| Voclosporin SCHEMBL13163177 | 1.00 | ABCB1 (0.86) | ABCB1PPIAPPP3CAMEN1NPC1 | |
| Voclosporin SCHEMBL13933936 | 1.00 | ABCB1 (0.86) | ABCB1PPIAPPP3CAMEN1NPC1 | |
| Voclosporin SCHEMBL12632344 | 1.00 | ABCB1 (0.86) | ABCB1PPIAPPP3CAMEN1NPC1 | |
| SCHEMBL25502320 | 0.97 | ABCB1 (0.83) | ABCB1PPIAPPP3CAMEN1NPC1 | |
| SCHEMBL13778742 | 0.96 | ABCB1 (0.79) | ABCB1PPIAPPP3CAMEN1NPC1 | |
| SCHEMBL19892676 | 0.95 | ABCB1 (0.78) | ABCB1PPIAPPP3CAMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1802 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107085-A1 | METHODS OF TREATING LUPUS WITH CD19-CD20 DUAL CAR-T CELLS | GENENTECH, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260140113-A1 | PROTEIN BIOMARKERS FOR USE IN LUPUS NEPHRITIS | EXAGEN INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4720666-A1 | METHODS FOR TREATING LUPUS NEPHRITIS WITH VOCLOSPORIN | Aurinia Pharmaceuticals Inc. (CA) | 2026-04-08 | — | — | EP | claimed |
| EP-4713684-A2 | TREATMENT OF AUTOIMMUNE DISORDERS WITH NK CELLS | Artiva Biotherapeutics, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4704886-A1 | TREATMENT OF AUTOIMMUNE DISEASES WITH BCMA-TARGETING ENGINEERED IMMUNE CELLS | Caribou Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4687943-A1 | METHODS AND USES RELATED TO ADMINISTRATION OF VOCLOSPORIN | Aurinia Pharmaceuticals Inc. (CA) | 2026-02-11 | — | — | EP | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| US-12528874-B2 | Methods and compositions for treating systemic lupus erythematosus (SLE) with mosunetuzumab | GENENTECH, INC. (US) | 2026-01-20 | — | — | US | claimed |
| US-20220288202-A1 | Use of Calcineurin Inhibitor Free CTLA4-IG + Anti-IL6/IL6R For Long Term Immunosuppression in Solid Organ Transplant Recipients | CEDARS-SINAI MEDICAL CENTER (US) | 2022-09-15 | — | — | US | claimed |
| WO-2022187607-A1 | PHARMACEUTICAL COMPOSITIONS WITH REDUCED SIDE EFFECT AND METHODS OF USING THE SAME | TLC BIOPHARMACEUTICALS, INC. (US) | 2022-09-09 | — | — | WO | claimed |
| WO-2022182638-A1 | COMPOSITIONS AND METHODS FOR CARDIOMYOCYTE TRANSPLANTATION | UNIVERSITY OF WASHINGTON (US) | 2022-09-01 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220226428-A1 | PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS | AURINIA PHARMACEUTICALS INC. (CA) | 2022-07-21 | — | — | US | claimed |
| WO-2022153250-A1 | PROTOCOL TO MINIMIZE CALCINEURIN INHIBITOR NEPHROTOXICITY | AURINIA PHARMACEUTICALS INC. (CA) | 2022-07-21 | — | — | WO | claimed |
| EP-4025596-A1 | USE OF CALCINEURIN INHIBITOR FREE CTLA4-IG + ANTI-IL6/IL6R FOR LONG TERM IMMUNOSUPPRESSION IN SOLID ORGAN TRANSPLANT RECIPIENTS | Cedars-Sinai Medical Center (US) | 2022-07-13 | — | — | EP | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| WO-2022047234-A1 | DRUG COMBINATION KITS AND METHODS OF DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533321-B2 | Polypeptide formulations for oral delivery | PTMS, IAPP, IGF1R | PPP3CA 1734/4885ABCB1 3597/4885PPIA 3756/4885 |
| US-12528874-B2 | Methods and compositions for treating systemic lupus erythematosus (SLE) with mosunetuzumab | CD209, SSB, CCND2 | PPP3CA 2112/4885ABCB1 2802/4885PPIA 4223/4885 |
| US-20260140113-A1 | PROTEIN BIOMARKERS FOR USE IN LUPUS NEPHRITIS | MMP12, MMP16, MMP11 | PPP3CA 799/4885ABCB1 2952/4885PPIA 694/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | PPP3CA 2197/4885ABCB1 1822/4885PPIA 3856/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PPP3CA 1424/4885ABCB1 2323/4885PPIA 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.